الدكتورة تشانليانج يانج

زميل باحث

البريد الإلكتروني

cyang@hbku.edu.qa

موقع المكتب

1469

الدكتورة تشانليانج يانج

زميل باحث

المؤهلات العلمية

PhD. In Basic Medical Sciences

M.S. in Immunology

الكيان

معهد قطر لبحوث الطب الحيوي

القسم

مركز بحث السكري

السيرة الذاتية

Dr. Chunliang Yang is a Research Fellow in the Diabetes Research Center at the Qatar Biomedical Research Institute (QBRI). She earned her Ph.D. in Immunology from Huazhong University of Science and Technology (HUST), under the mentorship of Prof. Cong-Yi Wang, a leading expert in diabetes immunology. During her doctoral and master's training at HUST, Dr. Yang specialized in dissecting the immunometabolic mechanisms underlying type 1 and type 2 diabetes, with a particular focus on the pathogenic roles of T cells and macrophages in disease progression.

Dr. Yang is highly skilled in establishing murine models of diabetes and employing advanced techniques in cellular immunology and metabolic phenotyping to investigate disease pathogenesis. Her productive research has led to multiple first-author publications in high-impact journals, including Molecular Therapy, in which her work has elucidated novel mechanisms involving the PDIA3 chaperone function and interferon regulatory factors in diabetes.

At QBRI, Dr. Yang continues to pursue her research interests at the intersection of immunology and metabolic diseases. She aims to further unravel the cellular crosstalk and immunometabolic pathways that contribute to diabetes and related metabolic disorders, with the ultimate goal of identifying novel therapeutic strategies.

PhD. In Basic Medical Sciences

Huazhong University of Science and Technology, China

2025

M.S. in Immunology

Huazhong University of Science and Technology, China

2021

B.S. in Medical Laboratory Technology

University of South China

2018

  • The genetic and epigenetic mechanisms underlying type 1 diabetes and related autoimmune disorders.
  • Immunometabolic crosstalk between key cell types (e.g., T cells, macrophages) and metabolic organs in the pathogenesis of obesity and type 2 diabetes.
  • Diet-derived metabolites or small molecules for the prevention and treatment of metabolic and autoimmune diseases.
  • The cellular and molecular mechanisms driving the recurrence of metabolic disorders following therapeutic intervention.

Research Fellow

Diabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University

2025 - Present

Yang, C. L., Wang, F. X., Luo, J. H., Rong, S. J., Lu, W. Y., Chen, Q. J., Xiao, J., Wang, T., Song, D. N., Liu, J., Mo, Q., Li, S., Chen, Y., Wang, Y. N., Liu, Y. J., Yan, T., Gu, W. K., Zhang, S., Xiong, F., Yu, Q. L., Zhang, Z. Y., Yang, P., Liu, S. W., Eizirik, D., Dong, L. L., Sun, F., & Wang, C. Y. (2024). PDIA3 orchestrates effector T cell program by serving as a chaperone to facilitate the non-canonical nuclear import of STAT1 and PKM2. Molecular Therapy, 32, 2778–2797. 

Sun, F., Yang, C. L., Wang, F. X., Rong, S. J., Luo, J. H., Lu, W. Y., Yue, T. T., Liu, S. W., & Wang, C. Y. (2023). The pancreatic draining lymph nodes (PLNs) serve as a pathogenic hub contributing to the development of type 1 diabetes. Cell Bioscience, 13(1), 156. 

Yang, C. L., Sun, F., Wang, F. X., Rong, S. J., Yue, T. T., Luo, J. H., Zhou, Q., Wang, C. Y., & Liu, S. W. (2022).  The interferon regulatory factors, a double-edged sword, in the pathogenesis of type 1 diabetes. Cellular Immunology, 379, 104590.

Luo, J. H., Wang, F. X., Zhao, J. W., Yang, C. L., Rong, S. J., Lu, W. Y., Chen, Q. J., Zhou, Q., Xiao, J., Wang, Y. N., Luo, X., Li, Y., Song, D. N., Chen, C., Zhang, C. L., Chen, S. H., Yang, P., Xiong, F., Yu, Q. L., Zhang, S., Liu, S. W., Sun, F., & Wang, C. Y. (2024).  PDIA3 defines a novel subset of adipose macrophages to exacerbate the development of obesity and metabolic disorders. Cell Metabolism, 36(10), 2262–2280.e5. 

Xie, H., Wang, Y. H., Liu, X., Gao, J., Yang, C., Huang, T., Zhang, L., Luo, X., Gao, Z., Wang, T., Yan, T., Liu, Y., Yang, P., Yu, Q., Liu, S., Wang, Y., Xiong, F., Zhang, S., Zhou, Q., & Wang, C. Y. (2023). SUMOylation of ERp44 enhances Ero1α ER retention contributing to the pathogenesis of obesity and insulin resistance. Metabolism. 139,155351.